Hjem
Havjin Jacobs bilde

Havjin Jacob

Seniorkonsulent, Forskningsseksjon
  • E-postHavjin.Jacob@uib.no
  • Telefon+47 55 58 85 71
  • Besøksadresse
    Armauer Hansens hus, Haukelandsveien 28
  • Postadresse
    Postboks 7804
    5020 BERGEN
Vitenskapelig artikkel
  • Vis forfatter(e) (2021). An mri-based radiomic prognostic index predicts poor outcome and specific genetic alterations in endometrial cancer. Journal of Clinical Medicine. 1-11.
  • Vis forfatter(e) (2019). Blood metabolites associate with prognosis in endometrial cancer. Metabolites. 1-15.
  • Vis forfatter(e) (2018). A four-microRNA classifier as a novel prognostic marker for tumor recurrence in stage II colon cancer. Scientific Reports. 1-9.
  • Vis forfatter(e) (2017). Identification of a sixteen-microRNA signature as prognostic biomarker for stage II and III colon cancer. OncoTarget. 87837-87847.
  • Vis forfatter(e) (2016). Prognostic significance of S100A4 expression in stage II and III colorectal cancer: results from a population-based series and a randomized phase III study on adjuvant chemotherapy. Cancer Medicine. 1840-1849.
Doktorgradsavhandling
  • Vis forfatter(e) (2018). Prognostic biomarkers in stage II and III colorectal cancer: A study with focus on microRNAs and S100A4.

Se fullstendig oversikt over publikasjoner i CRIStin.

1) An MRI-based radiomic prognostic index predicts poor outcome and specific genetic alterations in Endometrial cancer. JCM | Free Full-Text | An MRI-Based Radiomic Prognostic Index Predicts Poor Outcome and Specific Genetic Alterations in Endometrial Cancer (mdpi.com) 

2) A four miRNA classifier as a novel prognostic marker for tumor recurrence in stage II colon cancer.  https://www.ncbi.nlm.nih.gov/pubmed/29670141

3) Identification of a sixteen-microRNA signature as prognostic biomarker for stage II and III colon cancer. https://www.ncbi.nlm.nih.gov/pubmed/29152124

4) Prognostic significance of S100A4 expression in stage II and III colorectal cancer: results from a population-based series and a randomized phase III study on adjuvant chemotherapy. https://www.ncbi.nlm.nih.gov/pubmed/27273130